Nigrostriatal neuronal death in Parkinson's disease - a passive or an active genetically-controlled process?

被引:0
|
作者
Ziv, I
Barzilai, A
Offen, D
Nardi, N
Melamed, E
机构
[1] BEILINSON MED CTR, DEPT NEUROL, IL-49100 PETAH TIQWA, ISRAEL
[2] BEILINSON MED CTR, FELSENSTEIN RES INST, IL-49100 PETAH TIQWA, ISRAEL
[3] TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL
关键词
PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; GROWTH-FACTOR; DOPAMINE; APOPTOSIS; INHIBITORS; TOXICITY; 6-HYDROXYDOPAMINE; ACTIVATION; HYPOTHESIS;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cause for the rather selective degeneration of the nigrostriatal dopaminergic (DA) neurons in Parkinson's disease (PD) is still enigmatic. The major current hypothesis suggests that nigral neuronal death in PD is due to excessive oxidant stress generated by auto- and enzymatic oxidation of DA, formation of neuromelanin and presence of high concentrations of iron. Such cell death is generally regarded as a passive, necrotic process, mainly resulting from membrane lipid peroxidation, leading to its dysfunction and rupture and then to neuronal disintegration. We suggest a novel approach, that views neuronal degeneration in PD as an active process that occurs mainly the nuclear level. Our concept is based on the following observations: (1) Nigral histopathology in PD is characterized by a slow, protracted degeneration of individual neurons. We propose that it may be due to apoptosis [programmed cell-death (PCD), an active, genetically-controlled, intrinsic program of cell ''suicide''] rather than to necrotic cell death. (2) DA exerts antitumor effect on melanoma and neuroblastoma cells. (3) Many anticancer drugs, trigger PCD by causing DNA damage. (4) DA has been shown to be genotoxic. (5) We recently first showed that DA, the endogenous neurotransmitter in the nigra, can trigger apoptosis in cultured, postmitotic sympathetic neurons. (6) We have also shown that PC-12 cells, transfected with the bcl-2 gene (a proto-oncogene that inhibits PCD) are relatively resistant to DA-apoptotic effect. Degeneration of nigrostriatal neurons in PD may therefore be linked to dysregulation of the control mechanisms that normally restrain the PCD-triggering-potential of their own neurotransmitter.
引用
收藏
页码:69 / 76
页数:8
相关论文
共 50 条
  • [31] Does neuronal loss in Parkinson's disease involve programmed cell death?
    Andersen, JK
    BIOESSAYS, 2001, 23 (07) : 640 - 646
  • [32] The dopaminergic nigrostriatal system and Parkinson's disease: Molecular events in development, disease, and cell death, and new therapeutic strategies
    Hodaie, Mojgan
    Neimat, Joseph S.
    Lozano, Andres M.
    NEUROSURGERY, 2007, 60 (01) : 17 - 28
  • [33] Age and severity of nigrostriatal damage at onset of Parkinson's disease
    de la Fuente-Fernández, R
    Lim, AS
    Sossi, V
    Adam, MJ
    Ruth, TJ
    Calne, DB
    Stoessl, AJ
    Lee, CS
    SYNAPSE, 2003, 47 (02) : 152 - 158
  • [34] Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease
    Struzyna, Laura A.
    Browne, Kevin D.
    Brodnik, Zachary D.
    Burrell, Justin C.
    Harris, James P.
    Chen, H. Isaac
    Wolf, John A.
    Panzer, Kate V.
    Lim, James
    Duda, John E.
    Espana, Rodrigo A.
    Cullen, D. Kacy
    JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2018, 12 (07) : 1702 - 1716
  • [35] Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease
    Nicolaas I. Bohnen
    Satyanarayana Gedela
    Hiroto Kuwabara
    Gregory M. Constantine
    Chester A. Mathis
    Stephanie A. Studenski
    Robert Y. Moore
    Journal of Neurology, 2007, 254 : 84 - 90
  • [36] Onset pattern of nigrostriatal denervation in early Parkinson's disease
    Pineda-Pardo, Jose A.
    Sanchez-Ferro, Alvaro
    Monje, Mariana H. G.
    Pavese, Nicola
    Obeso, Jose A.
    BRAIN, 2022, 145 (03) : 1018 - 1028
  • [37] Probabilistic tractography study of the nigrostriatal pathway in Parkinson's disease
    Tagliente, S.
    Wilson, H.
    Chappell, Z.
    Yousaf, T.
    De Natale, E.
    Pagano, G.
    Politis, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 339 - 339
  • [38] Tissue Engineered Nigrostriatal Pathway for Treatment of Parkinson's Disease
    Duda, John
    Struzyna, Laura
    Browne, Kevin
    Chen, Isaac
    Wolf, John
    Cullen, Kacy
    MOVEMENT DISORDERS, 2017, 32 (12) : E6 - E6
  • [39] Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease
    Scherfler, Christoph
    Seppi, Klaus
    Mair, Katherina J.
    Donnemiller, Eveline
    Virgolini, Irene
    Wenning, Gregor K.
    Poewe, Werner
    BRAIN, 2012, 135 : 3348 - 3354
  • [40] Nigrostriatal dopamine transporter availability in early Parkinson's disease
    Fazio, Patrik
    Svenningsson, Per
    Cselenyi, Zsolt
    Halldin, Christer
    Farde, Lars
    Varrone, Andrea
    MOVEMENT DISORDERS, 2018, 33 (04) : 592 - 599